Literature DB >> 20367272

Pharmacotherapy of uveitis.

Frank F Lee1, Charles Stephen Foster.   

Abstract

IMPORTANCE OF THE FIELD: The term 'uveitis' covers a broad spectrum of ocular inflammation affecting the iris, ciliary body, and/or the choroid, all of which comprise the uveal tract. Severe cases of uveitis need be treated aggressively to prevent damage caused by chronic inflammation. Untreated or poorly managed cases can lead to ciliary body dysfunction, inadequate aqueous production, chorioretinal damage, and possibly blindness. AREAS COVERED IN THIS REVIEW: There are many medications that can be used to treat uveitis. Corticosteroids are available in several formulations: topical drops, regional injections, oral and intravenous. Immunomodulatory agents that can be used for uveitis are antimetabolites, T-cell inhibitors, alkylating agents, and biologic response modifiers. These medications, their appropriate uses, and side effect monitoring will be detailed. WHAT THE READER WILL GAIN: There is a stepladder approach to treatment of ocular inflammation. Corticosteroids are the treatment of choice for treating acute flares. Steroid free remission is the goal of therapy and can be achieved with the use of chemotherapeutic agents. Which medications are appropriate and how to escalate therapy will be reviewed. TAKE HOME MESSAGE: Chronic systemic corticosteroid therapy is not an acceptable long treatment plan for uveitis, unless all other medications have failed. Steroid sparing immunosuppressive therapy should be pursued as soon as acute flares of uveitis have been controlled.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20367272     DOI: 10.1517/14656561003713534

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  16 in total

1.  [Monitoring treatment with biologics in non-infectious uveitis].

Authors:  T Barisani-Asenbauer
Journal:  Ophthalmologe       Date:  2011-01       Impact factor: 1.059

2.  Tissue-specific production of MicroRNA-155 inhibits melanocortin 5 receptor-dependent suppressor macrophages to promote experimental autoimmune uveitis.

Authors:  Fauziyya Muhammad; Anna Trivett; Dawei Wang; Darren J Lee
Journal:  Eur J Immunol       Date:  2019-06-19       Impact factor: 5.532

3.  Signaling mechanisms of growth hormone-releasing hormone receptor in LPS-induced acute ocular inflammation.

Authors:  Wei Cheng Liang; Jia Lin Ren; Qiu Xiao Yu; Jian Li; Tsz Kin Ng; Wai Kit Chu; Yong Jie Qin; Kai On Chu; Andrew V Schally; Chi Pui Pang; Sun On Chan
Journal:  Proc Natl Acad Sci U S A       Date:  2020-03-02       Impact factor: 11.205

4.  [Retinal transcriptome profile in mice following dexamethasone treatment for endotoxin-induced uveitis].

Authors:  Y U Peng; Qiu Yiguo; Lin Ru; F U Xinyu; Hao Bingtao; Lei Bo
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2018-07-30

Review 5.  Systemic treatment of vitreous inflammation.

Authors:  John B Christoforidis; Susie Chang; Angela Jiang; Jillian Wang; Colleen M Cebulla
Journal:  Mediators Inflamm       Date:  2012-09-16       Impact factor: 4.711

Review 6.  Nanotechnology and nanotoxicology in retinopathy.

Authors:  Dong Hyun Jo; Tae Geol Lee; Jeong Hun Kim
Journal:  Int J Mol Sci       Date:  2011-11-23       Impact factor: 5.923

7.  Surveying uveitis specialists-a call for consensus.

Authors:  Emmett T Cunningham
Journal:  J Ophthalmic Inflamm Infect       Date:  2012-03-28

Review 8.  Systemic treatments for noninfectious vitreous inflammation.

Authors:  Angela Jiang; Jillian Wang; Malav Joshi; John Byron Christoforidis
Journal:  Mediators Inflamm       Date:  2013-11-20       Impact factor: 4.711

Review 9.  Review of Systemic Immunosuppression for Autoimmune Uveitis.

Authors:  Claudia Castiblanco; C Stephen Foster
Journal:  Ophthalmol Ther       Date:  2014-03-18

10.  Red eyes presenting with a fistulous lesion in the left lower extremity: a case report.

Authors:  Natalia Palmou Fontana; Enrique Judez Navarro; Oscar Martín Melero; Sergio Losa Palacios
Journal:  J Med Case Rep       Date:  2015-09-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.